GSK hands rare disease gene therapies over to Orchard
Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies.
Read More
Tag: Strimvelis
NICE publishes final draft guidelines backing GSK’s Strimvelis
Cost regulators for NHS funded therapies in England and Wales have now published final draft guidance approving GlaxoSmithKline’s gene therapy Strimvelis for an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
Read More
NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy
The National Institute for Health and Care Excellence has published draft guidance recommending GlaxoSmithKline’s gene therapy Strimvelis as an option for treating an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
